Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020094712 - COMBINATION OF PRMT5 INHIBITORS AND BCL-2 INHIBITORS

Publication Number WO/2020/094712
Publication Date 14.05.2020
International Application No. PCT/EP2019/080386
International Filing Date 06.11.2019
IPC
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED [GB]/[GB]
Inventors
  • BARBASH, Olena
Agents
  • TELFER, Ruth
Priority Data
62/757,35208.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION OF PRMT5 INHIBITORS AND BCL-2 INHIBITORS
(FR) COMBINAISON D'INHIBITEURS DE PRMT5 ET D'INHIBITEURS DE BCL-2
Abstract
(EN)
The present invention relates to a combination of a protein arginine methyltransferase 5 (PRMT5) inhibitor and a B cell lymphoma 2 (BCL-2) inhibitor and the use of this combination in the treatment of cancer. In specific instances of the invention the PRMT5 inhibitor may be a compound of Formula (I).
(FR)
La présente invention concerne une combinaison d'un inhibiteur de la protéine arginine méthyltransférase 5 (PRMT5) et d'un inhibiteur du lymphome des cellules B (BCL-2) et l'utilisation de cette combinaison dans le traitement du cancer. Dans des exemples spécifiques de l'invention, l'inhibiteur de PRMT5 peut être un composé de formule (I).
Latest bibliographic data on file with the International Bureau